Search
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawn[A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130] … Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020.
Etranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L44156] It delivers a copy of the deficient gene that results in cell transduction and an eventual increase in circulating factor IX activity. … [L45255] Etranacogene dezaparvovec was approved by the EMA in February 2023[L45439,L45444] and by Health Canada in October 2023.[L48801]
Categories: Complex MixturesLasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnIt gained approval by European Commission in March 2009. … Ligand Pharmaceuticals signed a license agreement with Sermonix Pharmaceuticals for the development and commercialization of oral lasofoxifene in the USA.
Delgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigational[L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508] … After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024.
Rucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigational[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 [A18745] and accelerated approval in December 2016. … Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair.
Terpin hydrate
go.drugbank.com/drugs/DB13163ApprovedWithdrawnIt was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate … Terpin hydrate is an expectorant, commonly used to loosen mucus and ease congestion in patients presenting with acute or chronic bronchitis, and related pulmonary conditions.
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigational[A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. … [A1499] Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form.
Amifostine
go.drugbank.com/drugs/DB01143ApprovedInvestigationalA phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
Categories: Compounds used in a research, industrial, or household settingBenfluorex
go.drugbank.com/drugs/DB09022ApprovedWithdrawnThe European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009. … This recommendation was based on the risks (especially fenfluramine-like cardiovascular side-effects) outweighing the benefits.
Categories: Drugs Used in DiabetesGefapixant
go.drugbank.com/drugs/DB15097ApprovedIt received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications. … [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601]